In human peripheral blood neutrophils or in myeloid PLB-985 cells differentiated towards a neutrophil-like phenotype, the peptide N-
Introduction
The formyl peptide receptor 1 (FPR 1 ) is a G protein coupled receptor (GPCR) responsive to Nformyl-methionyl-leucyl-phenylananine (f-Met-Leu-Phe), a possible model for proteins synthesized by the bacterial ribosome that could activate an innate form of immunity, notably the activation of neutrophil leukocytes [1] . The N-formyl-Met N-terminus is assembled in mitochondrial proteins/peptides as well, also synthesized by the prokaryotic molecular machinery, and there is evidence that FPR 1 -mediated chemotaxis of neutrophils to sterile tissue injury sites may be driven by such a damage-associated molecular pattern [2] . The peptide N-
isothiocyanate (f-Nle-Leu-Phe-Nle-Tyr-Lys-FITC) binds to and selectively activates FPR 1 and is submitted to receptor-and arrestin-mediated endocytosis in neutrophils [1] . The fluorescent peptide supports a cytofluorometric competition assay based on human neutrophils to evaluate the binding of unlabeled peptides and drugs to FPR 1 [3] . The neutrophil FPR 1 mediates many functional responses in addition to chemotaxis, such as the respiratory burst, adhesion, and secretion of lysosomal enzymes.
We recently illustrated GPCR-mediated endocytosis of antibody cargoes by intact cells using myc-tagged agonist peptide hormones and an anti-myc monoclonal antibody, the 4A6 clone, with a view on possible applications in diagnosis and therapy (e.g., toxin-conjugated antibodies in oncology). This bifunctional agonist strategy applied particularly well to large recombinant myctagged peptides, CCL19 and parathyroid hormone, that formed complexes with the anti-myc antibody in the extracellular fluid; the complexes were internalized in endosomes by their cognate receptors, CCR7 and PTH 1 R, respectively [4, 5] . A similar strategy applied to the bradykinin B 2 receptor concerned myc-KGP-B-9972, a synthetic tagged analog agonist that 4 carried some anti-myc antibody into receptor-expressing cells, but with a lesser efficacy [6] . This was due to either the relatively low, micromolar affinity of the agonist for the receptor or to its small size, leading to possible steric hindrance between the antibody and the receptor, two large molecules that must bind the bifunctional agonist at the same time. By analogy to other peptide hormones for which we have evaluated epitope-tagged agonists as carriers of antibody cargoes, we have designed and evaluated f-Nle-Leu-Phe-Nle-Tyr-Lys-myc, C-terminally extended with the 10-residue myc tag, as a putative bifunctional high affinity FPR 1 agonist. A further prolonged analog with a larger spacer between the N-terminal FPR 1 pharmacophore and the C-terminal epitope was also produced to address the steric hindrance issue. It was found that the relative affinities of the former bifunctional peptide for the monoclonal antibody and the FPR 1 are sufficient to explain its pharmacologic profile.
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Materials and methods
Cells and stimulation
The institutional research ethics board approved the anonymous use of human citrated blood from healthy volunteers to obtain leukocytes. PMNLs (essentially neutrophils) were prepared according to Fernandes et al. [7] , with some modifications. Briefly, after sedimentation of red blood cells in 2% dextran, PMNLs were aseptically purified by centrifugation on Ficoll-Paque cushions. Contaminating erythrocytes were removed by hypotonic lysis and PMNLs were resuspended (10 6 /ml) in DMEM without serum (for microscopy) or supplemented with 10 % FBS (for cytofluorometry). An undifferentiated myeloid cell line was used in most experiments, namely, the PLB 985 cell line [8] , originally obtained from the German Collection of Microorganisms and Cell Cultures. These lines were cultured in RPMI 1640 medium containing 10% FBS, pyruvate and antibiotics at 37°C in a 5% CO 2 humidified atmosphere and chemical induction of differentiation was based on adding dimethylsulfoxide (DMSO, 1.3% v/v) for 5 to 7 days in the culture medium, a step known to upregulate the expression of the human FPR 1 in these cells [9] .
Drugs
f-Nle-Leu-Phe-Nle-Tyr-Lys-FITC was purchased from Molecular Probes, f-Met-Leu-Phe, Met- AlexaFluor-488 conjugated form.
Cell stimulation, microscopy and cytofluorometry
Epifluorescence microscopy [5] and cytofluorometry were used to ascertain the cellular uptake 
Superoxide measurement
Differentiated PLB 985 cells support f-Met-Leu-Phe-induced the O 2 -release assay based on cytochrome c reduction that was applied as described [9] .
Data analysis
Numerical values are means ± SEM. Superoxide release values were compared with ANOVA ; InStat 3.05 computer program, GraphPad Software; San Diego, CA).
Results
f-Nle-Leu-Phe-Nle-Tyr-Lys-FITC is a highly selective agonist of the FPR 1 receptor [1] . After 30 min of cell stimulation (10 nM) at 37°C, it strongly labeled many (but not all) differentiated PLB 985 cells in a granular manner that was consistent with extra-nuclear endocytic vesicles (Fig. 1, upper row for the microscopy, Fig. 2 (Fig. 3) . The myc-tagged peptide f-Nle-Leu-Phe-Nle-Tyr-Lys-myc also competed with the fluorescent probe with a potency comparable with that of f-Met-Leu-Phe ( Fig.   9 3), but the prolonged design f-Nle-Leu-Phe-Nle-Tyr-Lys-(Asn-Gly) 5 -myc, a 26-mer, was ~300-fold less potent, suggesting that the receptor discriminates against long peptides.
Differentiated PLB 985 cells, apt for the endocytosis of f-Nle-Leu-Phe-Nle-Tyr-Lys-FITC, were further used to monitor the uptake of the fluorescent form of the anti-myc monoclonal antibody 4A6 (microscopy, Fig. 4 ). The used dilution of 4A6 corresponds to a nanomolar concentration.
There was a small non-specific cellular uptake of the fluorescence just superior to cell autofluorescence (data not shown) and that was not prevented by co-treatment with a 100-fold excess of a mixture of irrelevant murine monoclonal IgGs, suggesting that the small uptake is not mediated by the Fc--Met-Leu-Phe, at highly active concentrations (10-1000 nM), failed to increase the cellular labeling when co-incubated with fluorescent 4A6. At 10-1000 nM, f-Nle-Leu-Phe-Nle-Tyr-Lys-myc or the prolonged myc-tagged peptide were also inactive in this respect (Fig. 4) .
Both f-Met-Leu-Phe and f-Nle-Leu-Phe-Nle-Tyr-Lys-myc (10 nM) behaved as agonists in the superoxide release assay applied to differentiated PLB 985 cells (Fig. 5) . While the addition of the antibody 4A6 to the intact cells had no direct effect on the assay and did not abate the effect of f-Met-Leu-Phe, it decreased the effect of f-Nle-Leu-Phe-Nle-Tyr-Lys-myc in a concentrationdependent manner (significantly at 28 nM, Fig. 5 ), supporting a selective pre-receptor antagonism of the tagged peptide.
Discussion
In view of the increasing availability of therapeutic monoclonal antibodies that carry cytotoxic cargoes for anti-cancer therapy [11] or other conjugates supporting diagnostic procedures, we studied the feasibility of forcing intact cells to internalize known monoclonal antibodies by exploiting agonist-induced endocytosis of the FPR 1 triggered by a novel bifunctional agonist.
While a bifunctional FPR 1 ligand conjugated with an infrared fluorophore has been previously successfully designed and applied in live animals to detect inflammatory neutrophil accumulation [12] , this specific agent had a large spacer (polyethylene glycol 76 ) between the receptor-binding peptide and the fluorophore. The present strategy has produced the relatively small 16-mer peptide f-Nle-Leu-Phe-Nle-Tyr-Lys-myc, modelled on the high affinity fluorescent probe agonist f-Nle-Leu-Phe-Nle-Tyr-Lys-FITC, the fluorophore representing a comparatively small cargo compatible with receptor binding. However, microscopy failed to document the endocytosis of the antibodies in a situation where there is an approximate equimolar ratio of nanomolar concentrations of the ligand and the receptor (schematic representation: Fig. 6, left) ; in the presence of such a mixture, the agonist effect of the myc-tagged analog is not decreased (Fig. 5 ).
This implies that the bifunctional ligand has a higher affinity for the FPR 1 than for the antibodies.
However, increasing the antibody concentration revealed some pre-receptor antagonism (Figs. 5,   6 , right), proving that the tagged peptide binds to the antibodies in a sizeable manner; this antagonism did not apply to f-Met-Leu-Phe, showing specificity. Increasing the concentration of the myc-tagged agonist was not favorable to record the endocytosis of bound fluorescent antibodies (Fig. 4) due to either the excess of free agonist in the reaction or to some steric hindrance between the agonist-bound antibody and the receptor. The prolonged peptide f-NleLeu-Phe-Nle-Tyr-Lys-(Asn-Gly) 5 -myc, while presumably maintaining its affinity for the antibodies, did not bind well enough to the FPR 1 (Fig. 3) to directly address the issue of the role of steric hindrance in the system.
The present experimental system illustrates a variant of the modular cargo approach applied to bifunctional peptide ligands: the discrepancy between the ligand affinity for the receptor and that for the antibody may determine unfavorable stoichiometric ratios of the ligand/antibody concentrations to reach cargo endocytosis. 
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